DrugPatentWatch Database Preview
Patent: 10,383,930
» See Plans and Pricing
Summary for Patent: 10,383,930
| Title: | Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| Abstract: | A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer. |
| Inventor(s): | Mahr; Andrea (Tubingen, DE), Weinschenk; Toni (Aichwald, DE), Schoor; Oliver (Tubingen, DE), Fritsche; Jens (Dusslingen, DE), Singh; Harpreet (Munchen Schwabing, DE), Muller; Phillip (Kassel, DE), Leibold; Julia (Langkampfen, AT), Goldfinger; Valentina (Tubingen, DE) |
| Assignee: | IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE) |
| Application Number: | 16/100,498 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,383,930
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 002 | 2004-02-26 | Start Trial | IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE) | 2035-08-06 | RX | search | |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE) | 2035-08-06 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
